Pfizar started its four research units, in 2010, near to leading academic medical centers, or hospitals that are integrated with medical schools. These units were established in multiple cities, including San Francisco, New York, San Diego, and Boston. The basic objective of these research units was to promote and strengthen the collaboration between Pfizar and academic medical researchers with an aim to increase the innovation in drug development. In order to minimize the time, the project team comprised of academics working together with Pfizar scientists to quickly introduce a therapeutic drug to the market. This case determines a framework developed by Pfizar for the academic collaboration. What were the potential risks and opportunities associated with this framework? What could be the path to bring the framework to a leading position in the future? In what manners, the other prominent pharmaceutical companies’ framework can cause a threat for the Pfizar framework of academic collaboration?
Related Case Solutions & Analyses:
World Wide Technology and ClearOrbit: Enabling Supply Chain Collaboration
Progistix-Solutions Inc.–The Critical Parts Network
Marriott Corp. (A)
Brown Forman Distillers Corporation
Pepsi’s biodegradable backlash: the snack bag that was too noisy
Hightower Department Stores
The Clorox Company: Leveraging Green For Growth
Reorganizing Healthcare Delivery through a Value-Based Approach
Double Vision: Making Eye Care Accessible through Cross-Subsidization
From Blockbuster to Video on Demand: Distribution Channel Innovation in the U.S. Video-Rental Industry
